General Information of Drug (ID: DM0HZBU)

Drug Name
VP-025 Drug Info
Synonyms Inflammation therapeutics, Vasogen; VP-015
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM0HZBU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AD-452 DMMFLXN Rheumatoid arthritis FA20 Phase 2 [3]
IRX-2 DMODLN7 Acute myeloid leukaemia 2A60 Phase 2 [4]
JTE-607 DM1BQFY Sepsis 1G40-1G41 Discontinued in Phase 2 [5]
VG-106 DMY0V6J Solid tumour/cancer 2A00-2F9Z Terminated [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytokine receptor unspecific (CRF) TTXM6JN NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017461)
2 List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486.
3 Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9.
4 Clinical pipeline report, company report or official report of IRX Therapeutics.
5 JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8.
6 WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same.